Hartmut Ehrlich
29Patents
7h-index
42Co-inventors
69Inventor score
Filing activity: Dec 4, 1987 → Dec 6, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4992373A | Vectors and compounds for direct expression of activated human protein C | Chemistry; Metallurgy | 43 | Expired |
| US8450275B2 | TFPI inhibitors and methods of use | Physics | 12 | Active |
| US8466108B2 | TFPI inhibitors and methods of use | Emerging Cross-Sectional Technologies | 10 | Active |
| US5196322A | Vectors and compounds for expression of zymogen forms of human protein C | Chemistry; Metallurgy | 10 | Expired |
| US10201586B2 | TFPI inhibitors and methods of use | Physics | 10 | Active |
| US8962912B2 | Transgenic non-human animals expressing human blood clotting factors and uses thereof | Human Necessities | 10 | Active |
| US7968293B2 | IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease | Chemistry; Metallurgy | 9 | Active |
| US9512198B2 | FVIII peptides for immune tolerance induction and immunodiagnostics | Chemistry; Metallurgy | 5 | Active |
| US8969524B2 | FVIII peptides for immune tolerance induction and immunodiagnostics | Chemistry; Metallurgy | 5 | Active |
| US8216793B2 | Detection of antibody that binds to water soluble polymer-modified polypeptides | Physics | 3 | Active |
| US9463237B2 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses | Chemistry; Metallurgy | 3 | Active |
| US9018167B2 | TFPI inhibitors and methods of use | Physics | 3 | Active |
| US8852874B2 | Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro | Physics | 2 | Active |
| US10329583B2 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses | Chemistry; Metallurgy | 1 | Active |
| US11001613B2 | TFPI inhibitors and methods of use | Emerging Cross-Sectional Technologies | 1 | Active |
| US9556230B2 | TFPI inhibitors and methods of use | Physics | 1 | Active |
| US9777051B2 | TFPI inhibitors and methods of use | Emerging Cross-Sectional Technologies | 1 | Active |
| US11992499B2 | Quinoline derivatives for use in the treatment of inflammation diseases | Chemistry; Metallurgy | 0 | Active |
| US11266667B2 | ABX196 for use in the treatment of bladder cancer | Human Necessities | 0 | Active |
| US9884105B2 | Production of viral vaccine | Chemistry; Metallurgy | 0 | Active |
| US9046536B2 | Methods and compositions for treating bleeding disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US11826372B2 | Combinations including ABX196 for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US8986670B2 | IgG stimulated remyelination of peripheral nerves | Emerging Cross-Sectional Technologies | 0 | Active |
| US8632991B2 | Methods and compositions for treating bleeding disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US11278552B2 | Combinations including ABX196 for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.